Introduction: We investigated the health-related quality of life (HRQoL) of long-term prostate cancer patients who received leuprorelin acetate in microcapsules (LAM) for androgen-deprivation therapy (ADT). Methods: The observational study was carried out by 30 office-based German urologists in 536 prostate cancer (PCa) patients treated for ≥5 years with LAM and in 116 patients of an age-matched control group (CG). Data on HRQoL and health status was collected prospectively using validated questionnaires QLQ-C30, QLQ-PR25 and Karnofsky Index. Data on effectiveness (clinical response, prostate specific antigen [PSA], testosterone) and safety was collected retrospectively from patients' health records. We used descriptive statistics to analyze the data. Results: The mean treatment duration was 8.6 years (range 4.5-19.8 years). General health status (QLQ-C30) was comparable for both groups. Differences were observed regarding physical - and role functioning. ADT patients rated single items slightly worse than CG. Karnofsky-Index showed comparable high values (median of 90%). QLQ-PR25 revealed more PCa-related symptoms for ADT patients. Within 6 months, median PSA level declined >90% and median testosterone levels declined below castration level from 4.0 to 0.2 ng/mL. Clinical response (European Organisation for Research and Treatment of Cancer criteria) was observed in at least 90% of ADT patients. Conclusions: Long-term ADT with LAM is a well-accepted, tolerated, effective, and low-burden treatment option for patients with advanced, hormone-sensitive PCa.

Journal Section:
Original Paper
Keywords:
Prostate cancer, Androgen-deprivation therapy, Leuprorelin acetate, Health-related quality of life
1.
Robert Koch Institut: Bericht zum Krebsgeschehen in Deutschland 2016, Kapitel 2.6 Prostatakrebs (C60). Berlin, Robert Koch Institut, 2016.
2.
Leitlinienprogramm Onkologie: S3-Leitlinie Prostatakarzinom, Version 4.0, December 2016.
3.
Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-240.
4.
Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-244.
5.
Heidenreich A, Bastian PJ, Bellmunt J, et al: EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-479.
6.
Bubley GJ: Is the flare phenomenon clinically significant? Urology 2001;58(2 suppl 1):5-9.
7.
Redding TW, Schally AV: Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 1981;78:6509-6512.
8.
Tolis G, Ackman D, Stellos A, et al: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982;79:1658-1662.
9.
Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 1996;30(suppl 1):7-14; discussion 19-21.
10.
Tunn UW, Wiedey K: Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis 2009;12:83-87.
11.
Chu D, Popovic M, Chow E, et al: Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients. J Comp Eff Res 2014;3:523-531.
12.
Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-106.
13.
Hakenberg OW: Onkologie und Tumoren: Prostatakarzinom; in Schmelz HU, Sparwasser C, Weidner W (eds): Facharztwissen Urologie: Differenzierte Diagnostik und Therapie. Heidelberg, Springer-Verlag Berlin, 2014, vol. 3, pp 219-262.
14.
Bolla M, de Reijke TM, Van Tienhoven G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-2527.
15.
Eisenhardt A, Schneider T, Scheithe K, et al: [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: results of the non-interventional study TRIPTOSIX]. Urologe A 2016;55:176-183.
16.
Kerleau C, Guizard AV, Daubisse-Marliac L, et al: Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. Eur J Cancer 2016;63:143-153.
17.
Radlmaier A: Theoretisches modell über die entstehung von Hitzewallungen; in Nagel R (ed): Aktuelle Standortbestimmung der Konservativen Therapie des Prostatakarzinoms. New York, de Gruyter Berlin, 1990, pp 163-170.
18.
Higano CS: Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(suppl 2A):32-38.
19.
Bagrodia A, DiBlasio CJ, Wake RW, Derweesh IH: Adverse effects of androgen deprivation therapy in prostate cancer: current management issues. Indian J Urol 2009;25:169-176.
20.
Kumar RJ, Barqawi A, Crawford ED: Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005;7(suppl 5):37-43.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.